Hemostatics is a biopharmaceutical company developing CM‑352, a novel antifibrinolytic agent that stops bleeding by inhibiting fibrinolysis. The preclinical candidate targets life‑threatening hemorrhagic conditions such as intra‑cerebral hemorrhage, major surgery, trauma, and gastrointestinal bleeding, where current therapies are inadequate. In mouse models, CM‑352 reduced bleeding time by 89% and overall blood loss by 61%, demonstrating its potential efficacy.
Funding
$1.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Significant bleeding during major surgery, trauma, intracerebral hemorrhage, gastrointestinal bleeding, and certain gynecological and rare bleeding disorders leads to high mortality, morbidity, and reliance on blood transfusions, while existing antifibrinolytic therapies are insufficient for these life‑threatening conditions.
Solution
Hemostatics is developing CM‑352, a patented antifibrinolytic agent that directly inhibits fibrinolysis through a novel mechanism of action. In preclinical mouse models, CM‑352 reduced bleeding time by 89% and blood loss by 61%, demonstrating potent hemostatic activity. The drug is intended for use across a range of acute hemorrhagic indications, including major surgeries, traumatic injury, intracerebral hemorrhage, gastrointestinal bleeding, and bleeding disorders such as hemophilia and hereditary angioedema. By targeting the fibrinolytic pathway, CM‑352 aims to provide rapid bleeding control where current treatments are inadequate, potentially decreasing the need for transfusions and improving patient outcomes.
Target Audience
Primary customers are hospitals, trauma centers, and surgical teams seeking effective hemostatic agents for acute bleeding management, as well as specialty clinics treating patients with intracerebral hemorrhage, gastrointestinal bleeding, and inherited bleeding disorders.
Features
- Patented small‑molecule antifibrinolytic with a novel mechanism that directly blocks fibrinolysis
- Demonstrated preclinical efficacy: 89% reduction in bleeding time and 61% reduction in blood loss in mouse models
- Broad therapeutic scope covering surgery, trauma, intracerebral hemorrhage, gastrointestinal bleeding, gynecological bleeding, and rare bleeding disorders
- Designed for rapid onset of action to achieve immediate hemostasis in acute bleeding events
- Potential to reduce reliance on blood product transfusions and associated complications